Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Christie introduces CountertAct – a far-UVC light fixture


Christie CounterAct UV disinfection fixture

Christie CounterAct UV disinfection fixture

Zoran Veselic, president and COO, Christie, added: “The fact that far-UVC light – specifically, our new Christie CounterAct far-UVC fixture – can be used in the presence of people is a real differentiating factor.”

Christie® is pleased to announce the launch of the Christie® CounterAct™ line of commercial UV disinfection products with patented Care222® far-UVC light technology for cinemas, theme parks, museums, sports complexes and other indoor spaces. Unlike comparable products, the Christie fixture uses Ushio’s patented narrowband filtered Care222 excimer lamps that emit far-UVC 222nm light – the only UV technology shown to continuously and significantly reduce pathogens, like coronaviruses, that may also be used while people are present, when used in accordance with specified parameters. Mass production of the new Christie CounterAct fixture starts in January 2021.

Developed by Christie’s parent company, Ushio Inc., using IP licensed from Columbia University based on research by Columbia University’s Center for Radiological Research, the revolutionary Care222 far-UVC, mercury-free excimer lamp—highlighted in FORTUNE magazine’s annual Change the World list1 in 2020, includes a proprietary short pass filter that prevents the emission of longer wavelengths of UV light (230nm and higher) that are capable of penetrating human skin and eyes, an especially important feature that other 222nm and far-UVC products do not have.

Christie CounterAct introduces an added layer of defense against pathogens in indoor venues when guests and staff are present

Christie CounterAct is a line of fixtures that are simple to control remotely and can be installed on ceilings as easily as a commercial lighting fixture. It is well suited for use across a wide range of occupied, commercial areas such as entertainment venues, including lobbies, auditoriums, and restrooms, as well as other indoor spaces. Our first Christie CounterAct fixture contains two Care222 excimer far-UVC lamps that significantly reduce pathogens on surfaces of any indoor space. The fixture, with fast instant on/off at full output power and its Care222 technology lamps, has been shown effective at reducing pathogens in laboratory tests2. And unlike other UV technology, these fixtures with patented Care222 lamps may be used when people are present.

The background on UV light

It has been known for many years that UV light is a highly effective disinfectant that can reduce pathogens in indoor spaces. Businesses and other institutions have long used germicidal UVC light to stop the spread of viruses. The main drawback with most UVC technology is that it uses a 254nm wavelength that can penetrate human skin and eyes, which means these germicidal lights can only be used when people are not present or while they’re wearing personal protective equipment (PPE) that protects the eyes and skin. These shortcomings constrain how these devices must be operated and limit their widespread use in occupied indoor spaces.

A study3 conducted by Kobe University published in August 2020 concludes that, due to its shorter wavelength, far-UVC 222nm light does not penetrate the skin and therefore may be used when humans are present. Another recent study4 published in the American Journal of Infection Control shows that far-UVC 222nm light can effectively reduce more than 99.7% of surface contamination of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.

Researchers at Columbia University have also tested far-UVC 222nm light, and in particular its effect on aerosolized seasonal coronaviruses (that cause the common cold). A scientific paper published by this group in the Scientific Reports5 in June 2020 found that 99.9% of aerosolized seasonal coronaviruses (the cause of the common cold) were inactivated when exposed to far-UVC 222nm light in just 25 minutes.

These studies’ findings suggest that the filtered 222nm far-UVC light emitted by Care222 lamps in Christie’s CounterAct fixture, which can operate continuously even when people are present, offers a significant improvement over traditional manual cleaning alone, which requires professional cleaners, and the repeated use of harsh chemicals, in which the results are temporary.

Zoran Veselic, president and COO, Christie, added: “People are essential to the entertainment industry, and their level of comfort in public venues is paramount to the industry’s success. We are very proud to be able to offer this product with Ushio’s Care222 technology to our partners, and we are excited about the possibilities the technology will have in bringing customers back to the places they love, such as movie theaters and theme parks. The fact that far-UVC light – specifically, our new Christie CounterAct far-UVC fixture – can be used in the presence of people is a real differentiating factor. By harnessing these benefits as part of a user-friendly product that can be quickly deployed, we hope to provide a much-needed boost to our partners across the entertainment industry who are currently struggling to attract wary customers.”

For more information visit Christie’s CounterAct website.

1.FORTUNE Magazine’s Change the World highlights Ushio’s achievements in developing Care222® filtered Far UV-C disinfection modules, and the research conducted in collaboration with Japan’s Kobe University and Columbia University. Represented at number 40, Ushio stands alongside other companies that demonstrate measurable social impact and innovations within their industries by pioneering new technology or services.

2.The pathogen-reducing efficacy of Christie CounterAct products with patented Care222 technology and their use in occupied spaces is dependent on proper installation and operational specifications, in accordance with theAmerican Conference of Governmental Institutional Hygienist (ACGIH) guidelines. Link to ACGIH

3. Fukui T, Niikura T, Oda T, Kumabe Y, Ohashi H, et al. (2020) Exploratory clinical trial on the safety and bactericidal effect of 222-nm ultraviolet C irradiation in healthy humans. PLOS ONE 15(8): e0235948. Link to report

4. Kitigawa H, Nomura T, Nazmul T, Shigemoto N, Sakaguchi T, Ohge H, et al. (2020) Effectiveness of 222-nm ultraviolet light on disinfecting SARS-CoV-2 surface contamination. American Journal of Infection Control. Link to report

5. Buonanno, M., Welch, D., Shuryak, I. et al. (2020) Far-UVC light (222 nm) efficiently and safely inactivates airborne human coronaviruses. Sci Rep 10, 10285. Link to report

Notes:

Christie CounterAct products with patented Care222 technology are not for use on humans or animals or to disinfect medical devices.

The pathogen-reducing efficacy of Christie CounterAct products with patented Care222 technology and their use in occupied spaces is dependent on proper installation and operational specifications, in accordance with American Conference of Governmental Industrial Hygienists (ACGIH) guidelines

Any references to “disinfection” and “disinfecting” are referring generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition of the term as may be used for other purposes by the U.S. Food and Drug Administration or the U.S. Environmental Protection Agency.

“Christie” is a trademark of Christie Digital Systems USA, Inc., registered in the United States of America and certain other countries.

Share article on social media or email:

Elev8 Cannabis Names Naomi Granger as new Chief Financial Officer


Elev8 Cannabis, an emerging adults-medical cannabis company with a dispensary in Eugene, Oregon, Athol, Massachusetts, and two others to open by spring 2021, in Massachusetts, announced today that Naomi Granger was named Elev8 Cannabis chief financial officer. Granger becomes the company’s first CFO. Her appointment is effective immediately.

“Naomi brings the perfect balance of expertise and experiences to the role as Elev8 Cannabis continues to expand our multi-state dispensaries and strengthen our focus on providing excellent service and cannabis products for our customers,” said Seun Adedeji. “She has been an outstanding leader in the cannabis industry, having co-founded DOPE CFO and after delivering strong financial and operational management throughout her 15-year career working for “Big 4” accounting firms.”

After serving as CFO for dozens of cannabis companies and teaching proper cannabis accounting to over 600 accounting firms across the United States, Granger decided to launch Green Leaf CFO to further hone her skills in the ever changing cannabis industry, build stronger strategic partnerships and provide even more value to aspiring cannabis businesses.

“I am thrilled to join Elev8 Cannabis in this chief financial officer role, and I look forward to working closely with Elev8 as it continues growing and its value increases,” Granger said. “Seun has built a strong foundation for an enduring cannabis business, and I am poised to help Seun and the company expand on what he’s started by creating and implementing financial strategies that benefit the growth of Elev8 Cannabis.”

Granger’s appointment coincides with the opening of two additional Massachusetts Elev8 Cannabis dispensaries to open in early 2021 in Orange and Williamstown. “Having Naomi on board as we grow further into the state of Massachusetts is extremely important for Elev8 achieving the best in financial advising as well as for overseeing the best choices in order for it to remain profitable,” Adedeji said.

About Elev8 Cannabis

Elev8 Cannabis was founded by Seun Adedeji in 2017, to bring a variety of high-quality health and wellness cannabis products to the public. To learn more about Elv8 Cannabis promotions and dispensaries, visit http://www.elev8cannabis.com

Share article on social media or email:

RadSite Launches Specialty Accreditation Modules for Advanced Diagnostic Imaging


News Image

Dr. Browning adds, “As part of the accreditation process, RadSite continues to invest time and energy to educate and share best practices with organizations that apply for accreditation.”

RadSite,™ a leading accrediting organization promoting performance and quality-based imaging practices, recently launched the MIPPA Accreditation Program (MAP) Standards version 3.1, featuring more than a dozen specialty modules for advanced diagnostic imaging (ADI).

RadSite’s Standards Committee Chair, Eliot Siegel, MD, notes: “RadSite began working on the revised Standards late last year and worked closely with the RadSite Standards Committee members and other stakeholders, including payers and the U.S. Center for Medicare and Medicaid Services, to finalize the new specialty modules.” He adds that “RadSite also made several important updates to its professional experience, clinical protocol, and physics requirements.”

Currently, RadSite offers three MAP ADI accreditation programs covering CT, MRI, and Nuclear Medicine (i.e., PET, PET/CT and SPECT) imaging providers (also known as imaging suppliers). Successful RadSite applicants will continue to receive a general accreditation seal for each ADI modality, but also may apply and be recognized for one or more clinical subspecialty areas under MAP Standards version 3.1.

“RadSite’s accreditation review requirements were augmented to allow imaging providers to apply for each specialty exam type,” said Patrick Browning, MD, RadSite’s Chief Medical Officer. “Additional imaging exams must be submitted, evaluated, and scored as part of the enhanced technical evaluation to qualify for a specialty certification. Further, the new Standards require applicants to demonstrate experience and proficiency for each specialty module.” Dr. Browning also adds, “As part of the accreditation process, RadSite continues to invest time and energy to educate and share best practices with organizations that apply for accreditation.”

The following specialty modules will be covered going forward:

  • CT: Angiography, Body, Cardiac, Maxillofacial, Musculoskeletal, and Neurologic;
  • MRI: Angiography, Body, Breast, Cardiac, Functional, Musculoskeletal, and Neurologic; and
  • NucMed: Planar/SPECT – Cardiac and PET or PET/CT – Cardiac, Infection, Neurologic, Oncology.


“RadSite is working with several applicants who have recently applied for one or more of the new specialty modules,” notes Garry Carneal, JD, MA, RadSite’s President and CEO. “RadSite recently updated its online accreditation portal to ensure a seamless and meaningful review process for new and reaccreditation applicants, who now must apply under MAP Standards v 3.1.” RadSite’s online accreditation directory will highlight the new imaging specialty designations for each accredited imaging provider.”

Interested parties can download the new MAP Standards v 3.1 by clicking here. To register for a webinar discussing the new Standards, click here. To learn more about RadSite, visit http://www.radsitequality.com.

###

About RadSite™ (http://www.RadSiteQuality.com)

Founded in 2005, RadSite’s mission is to promote performance and quality-based practices for imaging systems across the U.S. and its territories. RadSite is recognized by the U.S. Centers for Medicare and Medicaid Services (CMS) as an official accreditation organization under the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008. RadSite’s programs help assess, track, and report imaging trends in an effort to enhance imaging procedures and outcomes. RadSite also offers educational programs, publishes issue briefs, and underwrites research on a complimentary basis to raise awareness of patient safety issues and to promote best practices. The organization is governed by an independent board and committee system, which is open to a wide range of volunteers to ensure transparency and accountability. To learn more about RadSite, please contact us at (443) 440-6007 or info@radsitequality.com.

Share article on social media or email:

Burlington Medical Introduces 3DLOOK, an Industry-First Self-Service, Body-Scanning Technology


3DLOOK body scanning technology

Digital provides a more accurate experience, from measure-to-measure consistency and the manufacturing of the radiation protection garment. The potential for this type of measuring is endless. Our goal is to continue using this cutting-edge technology well beyond the pandemic.

Burlington Medical, engineers of the highest quality and lightest weight radiation protection aprons in the industry, recently partnered with 3DLOOK to offer a touch-free radiation protection garment measuring and fitting experience. 3DLOOK’s patented body scanning technology enables Burlington Medical customers to get precise body measurements remotely with just two photos in under 30 seconds.

“This is an industry first,” says Murry Pitts, chief executive officer of Burlington Medical. “Digital provides a more accurate experience, from measure-to-measure consistency and the manufacturing of the radiation protection garment. The potential for this type of measuring is endless. Our goal is to continue using this cutting-edge technology well beyond the pandemic.”

3DLOOK standardizes the way that Burlington Medical measures for radiation protection garments, so customers will get a more accurate and consistent measurement. There’s no subjective measuring by hand or inconsistency from one measurer to the next. The 3DLOOK technology measures seamlessly from any location, any time. After taking or scanning two full-body images and submitting an order, each customer’s tailored apron is guaranteed to fit every inch of the wearer’s body.

“We spent a lot of time working with the incredible team at Burlington Medical and thinking about the user experience and convenience of digital measurements especially needed as COVID hit,” says Whitney Cathcart, CSO and co-founder of 3DLOOK. “There was a huge opportunity to deliver our contactless measuring solution immediately to help Burlington Medical continue to deliver customized radiation aprons efficiently. Their digital-first mindset sets a standard for other apparel companies to embrace our digital scanning solutions.”

During the pandemic and beyond, Burlington Medical is committed to the safety of all customers and staff. With 3DLOOK, there’s no need to risk person-to-person contact as all measurements can be made digitally. For added convenience, customers are able to store and access their measurements online, paving the way for a more streamlined ordering process.

It’s all possible through 3DLOOK’s partnership with Gerber Technology’s made-to-measure system. This allows companies like Burlington Medical to supplement their in-person fittings, operate online, and meet a greater customer demand, all while remaining digitally competitive and forward-thinking in the industry. The technology offers a simple way to digitize measurement capture and automate the entire workflow, which is needed now more than ever with COVID-19.

“Burlington Medical is a great example of an agile, future-oriented company,” says Karsten Newbury, chief strategy and digital officer at Gerber Technology. “The integration between our AccuMark Made-To-Measure platform and 3DLOOK helps Burlington to develop products meant for the shape and size of their actual customers. Systematically connecting their supply chain and leveraging data gives them the agility and efficiency to compete and win in today’s new reality.”

To learn more about 3DLOOK body scanning technology, visit burmed.com/3dlook/.

About Burlington Medical

Burlington Medical is an expert in the health and safety concerns of providers working in a radiation environment. From their virtual fitting services to industry-best lead times and cost-saving product options, Burlington Medical delivers superior outcomes with greater budget efficiency to all customers.

Burlington Medical is ISO9001 certified and follows all guidelines of the American Society for Testing and Materials (ASTM International). Burlington’s 5-year warranty is the best in the industry, compared to most competitors at just two years. Burlington’s quality products deliver more for the money, and with a registered nurse on the management team, Burlington brings an unparalleled level of insight and expertise to product development.

About 3DLOOK

Founded in 2016, 3DLOOK has built a patented mobile body scanning technology that uses a proprietary combination of computer vision, neural networks, and 3D statistical modeling to generate a 3D avatar and more than 70 points of measure of the human body from just two photos in under 30 seconds. The company has developed the world’s first Body Data Platform and was recognized as the 2019 winners of the LVMH Innovation Award and the IEEE Retail Digital Transformation Grand Challenge. 3DLOOK was previously named by Coresight Research as an emerging company disrupting traditional retail with its 3D body scanning technology.

Share article on social media or email:

Mconnect by Mask Capacity, Patent-pending PPE for the ‘Next Normal,’ Launches on Kickstarter


News Image

The global pandemic has created enough havoc in people’s day-to-day routine, now’s not the time anyone should be forced to sacrifice health, comfort and the ability to communicate clearly.

Wearing a face mask shouldn’t be a hassle since it’s now a part of everyday life. Staying safe, stylish and communicating clearly is possible all at once with the Mconnect face mask.

This patent-pending face mask is equipped with Bluetooth 5.0 technology for making phone calls, listening to music and facilitating clear conversations. The lightweight and comfortable fabric is baked in an antimicrobial solution to keep people protected from harmful pathogens. The innovative design paired with comfort and technology finally provides the option of wearing a ‘smart face mask.’

Currently, masks are the most important and powerful public health tool. That’s according to Robert Redfield, the Director of the Centers for Disease Control. Even with a COVID-19 vaccine, many health experts believe people will be wearing a mask well into 2021.

“The global pandemic has created enough havoc in people’s day-to-day routine, now’s not the time anyone should be forced to sacrifice health, comfort and the ability to communicate clearly,” said Brock Flint, Founder of Mask Capacity.

Mconnect’s patent-pending design prevents slipping, sliding or adjusting, and even prevents glasses from fogging up. The unique frame features gentle ear coverings for consumers to listen to their Bluetooth-connected device while still hearing the outside world and the mask lifts slightly off the mouth so users can speak clearly and be understood thanks to the built-in microphone.

The patent-pending Bluetooth feature also makes wearing a mask and staying connected easier than ever with a 45-foot wireless range. Plus, with a two hour charging time, Mconnect can get up to 12 hours of use and the battery offers 100 hours of standby time.

Mconnect is available to pre-order by visiting pr.go2.fund/Mconnect.

The Mconnect face mask helps people stay protected and connected. It’s not a new normal, Mconnect is the next normal.

About Mask Capacity

Mask Capacity strives to invent products and solutions that help everyday people prepare for and navigate the next normal of the COVID-19 global pandemic. The team believes everyone needs to do their part to fight this and other future outbreaks. For more information, visit https://producthype.co/mconnect/.

Share article on social media or email:

American Family Care Offering Hawaii Pre-Travel COVID-19 Tests


News Image

American Family Care’s expansive healthcare network has been a leader in the COVID-19 fight since day one. Our centers were among the first in the nation to offer rapid COVID testing, and we are thrilled to have been chosen to provide these crucial tests to travelers heading to Hawaii.

American Family Care (AFC), the nation’s leading provider of urgent care and accessible primary care, is at the top of a new list of trusted medical care providers partnering with the state of Hawaii to provide pre-travel COVID-19 testing for anyone planning to visit the tropical islands. AFC is now offering the pre-travel tests at more than 200 of its centers across the country.

“It is a great honor to have been selected as a trusted testing partner for the Safe Travels Hawaii program,” says AFC’s founder and CEO, Dr. Bruce Irwin. “AFC’s expansive healthcare network has been a leader in the COVID-19 fight since day one. Our centers were among the first in the nation to offer rapid COVID testing, and we are thrilled to have been chosen to provide these crucial tests to travelers heading to Hawaii.”

The state of Hawaii commenced pre-travel testing as part of a multi-layered screening process to allow travelers to safely come into the state without having to go through a 14-day quarantine. Travelers who follow all the processes, including getting a negative test from a Trusted Testing Partner, such as AFC, are not required to quarantine for 14 days.

Here is how the testing process works for anyone age 5 or older:

Hawaii Pre-Travel COVID-19 Testing

  • Complete a Nucleic Acid Amplification Test (NAAT) no more than 72 hours before flight travel time to Hawaii.
  • Hawaii will accept test results ONLY from participating locations of trusted providers like American Family Care.
  • Establish an account at the Safe Travels Hawaii program.
  • After testing, AFC staff will print out results so the information can be uploaded to the program’s website.
  • If test results are not available when arriving in Hawaii, travelers must self-quarantine until results are received and reported to Hawaii’s Department of Health.
  • If a traveler receives positive test results after arriving in Hawaii, they will be required to go into isolation until fully recovered.


Travelers who do not enter Hawaii with results from a Trusted Tested Partner will be required to self-quarantine for 14 days after their arrival.

About American Family Care:

Founded by Dr. Bruce Irwin with a single location in 1982, American Family Care has pioneered the concept of convenient, patient-centric healthcare. Today, with more than 200 clinics and 600 in-network physicians caring for nearly 3 million patients a year, AFC is the nation’s leading provider of urgent care, accessible primary care and occupational medicine. Ranked by Inc. magazine as one of the fastest-growing companies in the U.S., AFC’s stated mission is to provide the best healthcare possible, in a kind and caring environment, while respecting the rights of all patients, in an economical manner, at times and locations convenient to the patient. For more information, visit http://www.AmericanFamilyCare.com.

Share article on social media or email:

Nelson Hardiman Welcomes Alan J. Sedley as Senior Counsel


Nelson Hardiman Welcomes Alan J. Sedley as Senior Counsel

“We are thrilled to add an attorney with the wealth of healthcare experience thatAlan brings,” said Managing Partner Harry Nelson. “Alan brings not onlyexpertise, but also leadership that will strengthen our firm and extend supportto our clients.”

Alan J. Sedley, former general counsel of two California hospital health systems, has joined the law firm of Nelson Hardiman, LLP as Senior Counsel. “We are thrilled to add an attorney with the wealth of healthcare experience that Alan brings,” said Managing Partner Harry Nelson. “Alan brings not only expertise, but also leadership that will strengthen our firm and extend support to our clients.”

Sedley’s addition marks the firm’s ongoing growth and extension into Orange County, where he is based. “I am honcored and delighted to join Nelson Hardiman,” said Mr. Sedley. “It is a pleasure to be part of the best team of healthcare lawyers in the State.” Nelson Hardiman was recently recognized by U.S. News & World Report for yet another year as a “Tier 1 Law Firm for Healthcare and Regulatory Compliance Law”.

At Nelson Hardiman, Alan will draw on three decades of experience, including service as corporate in-house general counsel to two large California hospital health systems. As a hospital general counsel, Alan advised on numerous health system corporate matters, and managed transactions, litigation, regulatory compliance and operational processes at the hospitals. In his private practice and as outside counsel, Alan regularly advises and represents hospitals, health systems, physicians and other health professionals, ambulatory surgical centers and multi-specialty medical groups in their oft-challenging operational issues, addressing the traditional business and legal concerns within the context of the healthcare marketplace. Alan has pursued a specialized focus and offers highly experienced and dedicated counsel to large medical group and hospital medical staffs on issues relating to medical staff credentialing, privileging, physician recruitment, peer review analyses arising from suspected practitioner clinical deficiencies or disruptive conduct, and peer review body and committee investigatory processes. He provides detailed guidance on peer review hearing procedures as well as statutory reporting requirements. A civil litigator for the past thirty-five years, Alan has successfully litigated dozens of lawsuits in federal court on behalf of DSH hospitals and GME academic medical centers against the Centers for Medicare and Medicaid, alleging misapplication of rules and regulations during the course of computing hospital reimbursement payments.

About Nelson Hardiman

Nelson Hardiman LLP is the premier healthcare and life sciences firm in Los Angeles, serving healthcare and life science providers, investors, and organizations that need a hard-to-find level of quality advice on the most sensitive industry issues. The firm’s litigation practice specializes in defending fraud and abuse and whistleblower actions, government investigations, and other complex business disputes. Nelson Hardiman’s transactional group handles healthcare organization acquisitions, sales, investment, and financings, and Nelson Hardiman’s regulatory team advises on compliance with licensing, operational, and reimbursement issues across the full continuum of healthcare industry sectors, with expertise on Medicare and Medicaid requirements, privacy and data security, FDA, and other regulatory matters. The firm has earned a singular position reputation nationally for its leadership in addressing issues in behavioral health and telehealth. More information about the firm is available at http://www.nelsonhardiman.com or at 310.203.2800.

Share article on social media or email:

Relatient Ranked Number 464 Fastest-Growing Company in North America on Deloitte’s 2020 Technology Fast 500™


News Image

“The need to bridge the gap between healthcare providers and their patients to drive better outcomes and improve patient experiences has increased in past years, but especially during the pandemic,” said Michele Perry, CEO of Relatient. “We are growing to reflect this need.”

Relatient, a SaaS-based patient engagement company, today announced it ranked 464 on Deloitte’s Technology Fast 500, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 26th year. Relatient grew 195% during this period.

Relatient’s chief executive officer, Michele Perry, credits Relatient’s team and Healthcare’s need to engage with patients with the company’s 195% revenue growth. She said, “The Relatient team is honored to be included on Deloitte’s Fast 500 List for the third year in a row. The need to bridge the gap between healthcare providers and their patients to drive better outcomes and improve patient experiences has increased in past years, but especially during the pandemic. We are growing to reflect this need.”

“For more than 25 years, we’ve been honoring companies that define the cutting edge and this year’s Technology Fast 500 list is proof positive that technology — from software and digital media platforms, to biotech — truly does permeate so many facets of our lives,” said Paul Silverglate, vice chairman, Deloitte LLP and U.S. technology sector leader. “We congratulate this year’s winners, especially during a time when innovation is needed more than ever to address the monumental challenges posed by the pandemic.”

“Each year the Technology Fast 500 listing validates how important technology innovation is to our daily lives. It was interesting to see this year that while software companies continued to dominate, biotech companies rose to the top of the winners list for the first time, demonstrating that new categories of innovation are accelerating in the pursuit of making life easier, safer and more productive,” said Mohana Dissanayake, partner, Deloitte & Touche LLP, and industry leader for technology, media and telecommunications, within Deloitte’s audit and assurance practice. “We extend sincere congratulations to these well-deserved winners — who all embody a spirit of curiosity, and a never-ending commitment to making technology advancements possible.”

Overall, 2020 Technology Fast 500™ companies achieved revenue growth ranging from 175% to 106,508% from 2016 to 2019, with median growth of 450%.

About Deloitte’s 2020 Technology Fast 500™

Now in its 26th year, Deloitte’s Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2016 to 2019.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $US50,000, and current-year operating revenues of at least $US5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Relatient

Relatient, Inc., the 2020 KLAS Category Leader in Patient Outreach, is a SaaS-based patient-centered engagement company that utilizes a modern and mobile-first approach to improve patient and provider communication. On behalf of U.S. medical practices and health systems, Relatient engaged patients with more than 132 million messages in 2019. Relatient’s platform integrates with over 87 practice management systems and electronic health databases to drive operational efficiency, appointments and reviews, reduce no-shows, speed patient payments, and improve patient satisfaction, all while supporting health and care quality initiatives. For more information, visit http://www.relatient.net.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see http://www.deloitte.com/about to learn more about our global network of member firms.

Share article on social media or email:

UMD Researcher Receives NIH Funding to Develop a Novel Approach to Vaccination Against a Wide Range of Enteroviruses in a Single Vaccine


Poliovirus 3-D illustration, Credit: Shutterstock

Poliovirus 3-D illustration, Credit: Shutterstock

“The central idea is to switch from making vaccines that target individual outer shells [of viruses] to vaccines that target conserved replication proteins to potentially generate a vaccine product that could be protective against a much broader spectrum of enteroviruses,” says Belov.

With a new grant from the National Institutes of Health (NIH), the University of Maryland (UMD) is working to develop a novel approach to vaccination with the potential to provide broad-spectrum protection against hundreds of viruses in a single vaccine, from polio to the common cold. Enteroviruses are a diverse group of viruses creating a huge public health burden, including the poliovirus, rhinoviruses that are the major cause of the common cold, enterovirus 71 that causes hand-foot-and-mouth disease in children, and others that are associated with the development of diabetes like coxsackieviruses. But because of this diversity, only polio and enterovirus 71 have currently available vaccine products. By changing the way vaccines are developed, targeting the conserved replication proteins that are common among most enteroviruses instead of the structural proteins that are distinct to each of the hundreds of known enteroviruses, UMD’s College of Agriculture and Natural Resources will explore the potential to confer protection against a broad spectrum of enteroviruses in a single vaccine product, with major implications for public health.

“All viruses are pretty much like a nut,” explains George Belov, associate professor in Veterinary Medicine at UMD and lead investigator of this work. “You have the shell or husk, and then the material inside the husk. On the outside, the structural proteins look sufficiently different so that that immune response developed against one virus does not work against another. But inside, you have pretty much the same core of proteins the virus uses to replicate. The replication machinery of all of those viruses is very similar. So the central idea of this grant is to switch from making vaccines that target those individual outer shells to vaccines that target conserved replication proteins to potentially generate a vaccine product that could be protective against a much broader spectrum of enteroviruses.”

The technology to achieve this goal has only recently become available with constructs that Belov and his team developed to redirect the immune response when encountering a new virus. “What you need to do is remove the input of the outer structural proteins and present the immune system with only the antigens that come from the conserved replication proteins,” says Belov. “And we have a tool now to do this with constructs that don’t express the structural proteins. We want to see if this will be protective and if that protection extends across a broader spectrum of enteroviruses.”

This is a roughly $500K proof-of-concept grant that, if successful, could represent a shift in the way that vaccine products are produced and significantly reduce the burden of vaccination for a public that is increasingly concerned about the growing number of necessary vaccines.

“It’s always a risk-benefit question, because the more vaccines you add, the chances of getting complications from a vaccine product are higher. The risk is very low as a whole, but there is no absolutely risk-free product, and there are always people that will respond differently. So if you can protect against multiple viruses in the same product, that is a very desirable thing.”

With this initial funding in collaboration with Konstantin Chumakov at the Food and Drug Administration Office of Vaccines Research and Review, Belov and his team will be focusing on comparing this new vaccine approach to the existing vaccination products for poliovirus.

“You currently have three different serotypes of poliovirus with three vaccines, but the replication proteins are essentially the same,” says Belov. “With this grant, we want to vaccinate with the construct we developed that expresses conserved proteins and see if the product will protect against those three different serotypes of polio compared to the current established vaccine products. We have good preliminary data that supports this idea, but the ultimate test is in how the animal immune system will respond. Further, we will test if it works against non-polio viruses. Enteroviruses are a very broad group of viruses, so broad protection is very valuable.”

This problem is one that is common not just in enteroviruses, but across all forms of vaccine development. “If you want to develop a vaccine for COVID-19, for example, you currently have to make something that is specific to the structural proteins of COVID-19. But if you could make something that is effective across all types of coronaviruses by targeting the replication proteins, you could protect against a large spectrum of coronaviruses, the ones that we know of now and the ones that may come down the road as new virus threats.”

Belov has been working with enteroviruses for more than 20 years and is interested in their functionality on a cellular level. “Vaccine development is very important, but enteroviruses are fascinating in terms of what they do with the cell. A cell with an enterovirus changes its metabolism completely in a matter of hours. It can completely overrun all cell control mechanisms, so the cell basically becomes a zombie that does nothing but produce copies of the virus. It’s interesting for both the virologist and the cell biologist because the virus exposes the mechanisms that are difficult to observe in a noninfected cell. And that is my expertise – virus-cell interactions.”

While this work has direct application in vaccine development, Belov stresses that it could not be achieved without basic fundamental research. “The most important thing in science is fundamental research because you are only as good in vaccine development and therapeutics as your understanding of how the mechanism works on a cellular level. Applied research without the fundamental research is like trying to fix a TV by just hitting it without understanding what’s inside. Sometimes it works, but you don’t know why it does or doesn’t work without that deeper knowledge.”

This work is funded by the National Institutes of Health (NIH), Award #R21AI153976.

Share article on social media or email:

American Bone Health announces Kathleen Cody retiring as Executive Director, Cheryl Hostinak to take over


Kathleen Cody led American Bone Health for 20 years and guided the organization into its current mission of consumer engagement and community education.

American Bone Health, the leading nonprofit organization dedicated to promoting healthy bones through community education, announces Kathleen Cody is retiring as Executive Director after 20 years in the position, and that Cheryl Hostinak will succeed her as Executive Director on Jan. 1, 2021. The leadership succession plan will ensure a smooth transition as the fast-growing advocacy organization moves forward after its 30th anniversary.

Cody, who joined American Bone Health in 2001, guided the organization through a major change in its mission. Founded in 1990 in Oakland, Calif., American Bone Health initially conducted clinical research and offered bone density testing. The Board of Directors recognized that the organization could make a greater impact by focusing on empowering consumers to make healthy choices. Cody executed this strategy by developing American Bone Health’s signature educational programs and training a national network of volunteer Peer Educators. More recently, Cody has increased the public profile of American Bone Health through collaborations with other disease advocacy organizations, industry partners, and health care institutions.

“Kathleen Cody has been a dynamic and innovative leader for American Bone Health for 20 years, and she has been the face of the organization in the communities we serve and in the bone health field,” said Paul Cline, President of the Board of Directors of American Bone Health. “We are delighted to have found in Cheryl Hostinak a successor who brings strong knowledge in the bone health field and a wealth of experience in engaging with consumers. Cheryl has already been working with the American Bone Health team to ensure a seamless transition once she takes over full time as Executive Director at the first of the year. American Bone Health is poised for continued growth and success with Cheryl at the helm.”

“I am so grateful for all the great people I’ve worked with and the relationships that American Bone Health has built in communities all over the country,” Cody said. “Raising awareness about bone health and how to prevent osteoporosis and fractures is a critical mission, and we have really made a lot of difference by reaching out to people in the communities where they live. There is still a lot of work to be done, but we have built a great team, and I’m confident that once Cheryl takes over, American Bone Health won’t miss a beat.”

Hostinak is a highly accomplished leader with a wealth of experience in the life sciences and biopharmaceutical industries, particularly women’s health and bone health. Her roles have included patient engagement, advocate relations, marketing, business development, strategic planning, market research and clinical development.

“I am honored to have this opportunity to lead American Bone Health and build on what Kathleen, her team, the Board of Directors and all the wonderful volunteer Peer Educators have accomplished,” Hostinak said. “My passion is improving patient health outcomes, and I have worked closely with patient advocacy organizations in my career. I look forward to expanding American Bone Health’s reach so we can engage, educate and empower even more people to build and keep strong bones and prevent bone loss and fractures.”

About American Bone Health

American Bone Health is a national, community-based organization that teaches people how to build and keep strong and healthy bones for life with practical and up-to-date information and resources to inspire them to prevent bone loss, osteoporosis and fractures. Learn more at https://americanbonehealth.org and @ambonehealth.

Share article on social media or email: